Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tawanda Gumbo

Showing results (181-190 of 204) with videos related to

Pageof 21
Sort By:
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 19, 2017
Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatmentIsaac Zentner, Chawangwa Modongo, Nicola M Zetola, et al.
Applied and Environmental Microbiology|July 24, 2012
Mycobacterial shuttle vectors designed for high-level protein expression in infected macrophagesJennifer L Eitson, Jennifer J Medeiros, Ashley R Hoover, et al.
The Journal of Antimicrobial Chemotherapy|August 5, 2022
Potency of the novel PolC DNA polymerase inhibitor CRS0540 in a disseminated Listeria monocytogenes intracellular hollow-fibre modelSwati Patel, Moti Chapagain, Clifford Mason, et al.
Antimicrobial Agents and Chemotherapy|January 16, 2025
Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosisVanessa B Vogensen, Sanjay Singh, Christopher J Allende, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 28, 2019
Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End TuberculosisJan-Willem C Alffenaar, Tawanda Gumbo, Kelly E Dooley, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant TuberculosisDevyani Deshpande, Jotam G Pasipanodya, Shashikant Srivastava, et al.
International Journal of Antimicrobial Agents|May 15, 2023
Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus diseaseSanjay Singh, Jann-Yuan Wang, Scott K Heysell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant TuberculosisDevyani Deshpande, Jotam G Pasipanodya, Stellah G Mpagama, et al.
Antimicrobial Agents and Chemotherapy|October 27, 2020
Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant TuberculosisSuresh Mallikaarjun, Moti L Chapagain, Tomohiro Sasaki, et al.
Antimicrobial Agents and Chemotherapy|July 20, 2007
Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosingWilliam W Hope, Nita L Seibel, Cindy L Schwartz, et al.
Pageof 21

Showing results (181-190 of 204) with videos related to

Sort By:
Pageof 21
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 19, 2017
Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatmentIsaac Zentner, Chawangwa Modongo, Nicola M Zetola, et al.
Applied and Environmental Microbiology|July 24, 2012
Mycobacterial shuttle vectors designed for high-level protein expression in infected macrophagesJennifer L Eitson, Jennifer J Medeiros, Ashley R Hoover, et al.
The Journal of Antimicrobial Chemotherapy|August 5, 2022
Potency of the novel PolC DNA polymerase inhibitor CRS0540 in a disseminated Listeria monocytogenes intracellular hollow-fibre modelSwati Patel, Moti Chapagain, Clifford Mason, et al.
Antimicrobial Agents and Chemotherapy|January 16, 2025
Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosisVanessa B Vogensen, Sanjay Singh, Christopher J Allende, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 28, 2019
Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End TuberculosisJan-Willem C Alffenaar, Tawanda Gumbo, Kelly E Dooley, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant TuberculosisDevyani Deshpande, Jotam G Pasipanodya, Shashikant Srivastava, et al.
International Journal of Antimicrobial Agents|May 15, 2023
Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus diseaseSanjay Singh, Jann-Yuan Wang, Scott K Heysell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant TuberculosisDevyani Deshpande, Jotam G Pasipanodya, Stellah G Mpagama, et al.
Antimicrobial Agents and Chemotherapy|October 27, 2020
Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant TuberculosisSuresh Mallikaarjun, Moti L Chapagain, Tomohiro Sasaki, et al.
Antimicrobial Agents and Chemotherapy|July 20, 2007
Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosingWilliam W Hope, Nita L Seibel, Cindy L Schwartz, et al.
Pageof 21